|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2011-4-25
|
|
pubmed:abstractText |
In approximately 70% of patients with hepatocellular carcinoma (HCC) treated by resection or ablation, disease recurs within 5 years. Although gene expression signatures have been associated with outcome, there is no method to predict recurrence based on combined clinical, pathology, and genomic data (from tumor and cirrhotic tissue). We evaluated gene expression signatures associated with outcome in a large cohort of patients with early stage (Barcelona-Clinic Liver Cancer 0/A), single-nodule HCC and heterogeneity of signatures within tumor tissues.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
1528-0012
|
|
pubmed:author |
pubmed-author:AlsinetClaraC,
pubmed-author:AprilCraigC,
pubmed-author:BattistonCarloC,
pubmed-author:BruixJordiJ,
pubmed-author:CornellaHelenaH,
pubmed-author:FanJian-BingJB,
pubmed-author:HoshidaYujinY,
pubmed-author:KobayashiMasahiroM,
pubmed-author:KumadaHiromitsuH,
pubmed-author:LiberzonArthurA,
pubmed-author:LlovetJosep MJM,
pubmed-author:MazzaferroVincenzoV,
pubmed-author:NewellPhilippaP,
pubmed-author:RoayaieSasanS,
pubmed-author:SchwartzMyron EME,
pubmed-author:SiaDanielaD,
pubmed-author:ThungSwan NSN,
pubmed-author:TovarVictoriaV,
pubmed-author:VillanuevaAugustoA
|
|
pubmed:copyrightInfo |
Copyright © 2011 AGA Institute. Published by Elsevier Inc. All rights reserved.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
140
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1501-12.e2
|
|
pubmed:meshHeading |
pubmed-meshheading:21320499-Carcinoma, Hepatocellular,
pubmed-meshheading:21320499-DNA, Neoplasm,
pubmed-meshheading:21320499-Female,
pubmed-meshheading:21320499-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:21320499-Genotype,
pubmed-meshheading:21320499-Hepatectomy,
pubmed-meshheading:21320499-Humans,
pubmed-meshheading:21320499-Incidence,
pubmed-meshheading:21320499-Italy,
pubmed-meshheading:21320499-Japan,
pubmed-meshheading:21320499-Liver Neoplasms,
pubmed-meshheading:21320499-Male,
pubmed-meshheading:21320499-Middle Aged,
pubmed-meshheading:21320499-Neoplasm Recurrence, Local,
pubmed-meshheading:21320499-Prognosis,
pubmed-meshheading:21320499-Spain,
pubmed-meshheading:21320499-Survival Rate,
pubmed-meshheading:21320499-Tumor Markers, Biological,
pubmed-meshheading:21320499-United States
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma.
|
|
pubmed:affiliation |
HCC Translational Research Laboratory, Barcelona-Clinic Liver Cancer Group, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Liver Unit, Hospital Clinic, Barcelona, Spain.
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Research Support, N.I.H., Extramural
|
